Company Encyclopedia
View More
name
Goldman Sachs Future Health Care Equity ETF
GDOC.US
News
View More

Insulet Corp. Stock Underperforms Tuesday When Compared To Competitors

Insulet Corp.'s stock fell 2.08% to $285.50 on Tuesday, underperforming compared to competitors like Eli Lilly, DexCom, and Johnson & Johnson, despite a positive trading session for the market. The stock is 19.55% below its 52-week high. Trading volume was below the 50-day average.

Dow Jones·
US
PODD
-2.08%
Dow Jones·
US
PODD
-2.08%

US health agency to negotiate prices for GLP-1 weight-loss drugs

Dec 23 (Reuters) - The U.S. Centers for Medicare and Medicaid Services said on Tuesday it will negotiate drug prices with manufacturers of GLP-1 medications, in an attempt to expand access to the weight-loss treatments.Under the initiative, CMS would expand the coverage efforts, with a Medicaid pilot program beginning in May 2026 and a Medicare pilot in January 2027.The programs would cover Novo Nordisk’s (NOVOb.CO) , Wegovy and Ozempic, and Eli Lilly’sZepbound and Mounjaro for weight loss.

Reuters·
US
LLY
-0.45%
US
NVO
+7.30%
Reuters·
US
LLY
-0.45%
US
NVO
+7.30%

Sector Update: Health Care Stocks Mixed Late Afternoon

Health care stocks showed mixed performance, with NYSE Health Care Index slightly up and XLV down 0.3%. Pfizer shares fell 1.4% due to a trial participant's death. Novo Nordisk shares rose over 7% after FDA approved its Wegovy pill. Johnson & Johnson was ordered to pay $1.5 billion in a talc-related lawsuit, causing shares to drop 1%. RxSight shares fell over 10% following CFO transition announcement.

fidelity·
US
NVO
+7.30%
US
PFE
-1.31%
US
JNJ
-0.74%
fidelity·
US
NVO
+7.30%
US
PFE
-1.31%
US
JNJ
-0.74%

Key facts: Eli Lilly's orforglipron achieves 12.4% weight loss; Zepbound surpasses Wegovy; Operating margin rises to 40.9%

Eli Lilly's orforglipron, a daily oral GLP-1 agonist, showed 12.4% weight loss in trials. The FDA application is submitted, with a planned price of $149 per month.12Eli Lilly's weight-loss drug Zepbound outperformed Novo Nordisk's Wegovy in a study, leading analysts to predict Zepbound will surpass Wegovy sales by 2025.3Eli Lilly's adjusted operating margin has risen by 20.8 percentage points over the past two years, now standing at 40.9% for the trailing 12 months, highlighting enhanced profitability.4

TradingView·
US
LLY
-0.45%
TradingView·
US
LLY
-0.45%

Top Pharmaceutical Stocks To Add to Your Watchlist - December 23rd

MarketBeat highlights seven pharmaceutical stocks to watch: Novo Nordisk, Eli Lilly, Pfizer, Bristol Myers Squibb, AbbVie, Abbott Laboratories, and Gilead Sciences. These companies are noted for their high trading volumes and potential for substantial returns, driven by factors like clinical trial results and regulatory approvals. However, they also carry risks such as volatility and regulatory challenges. The report provides insights into each company's focus areas and recent developments.

Market Beat·
US
NVO
+7.30%
US
LLY
-0.45%
US
ABT
-0.53%
Market Beat·
US
NVO
+7.30%
US
LLY
-0.45%
US
ABT
-0.53%
© 2025 Longbridge｜Disclaimer